We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.

The article presents arguments supporting the need for randomized clinical trials for testing disease-modifying therapies (DMTs) for treating multiple sclerosis (MS) in pregnant women. It talks about topics including DMT guidance for managing MS in women who wish to conceive, the impact of DMTs on breastfeeding, and testing the safety of DMTs to pregnant women and fetuses.